KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Medtronic (MDT) over the last 12 years, with Q4 2025 value amounting to $38.0 million.

  • Medtronic's Asset Writedowns and Impairment rose 4074.07% to $38.0 million in Q4 2025 from the same period last year, while for Oct 2025 it was $144.0 million, marking a year-over-year decrease of 6200.53%. This contributed to the annual value of $123.0 million for FY2025, which is 6684.64% down from last year.
  • Latest data reveals that Medtronic reported Asset Writedowns and Impairment of $38.0 million as of Q4 2025, which was up 4074.07% from $28.0 million recorded in Q3 2025.
  • Medtronic's 5-year Asset Writedowns and Impairment high stood at $515.0 million for Q3 2021, and its period low was $13.0 million during Q1 2023.
  • Its 5-year average for Asset Writedowns and Impairment is $70.0 million, with a median of $25.0 million in 2021.
  • As far as peak fluctuations go, Medtronic's Asset Writedowns and Impairment plummeted by 9708.74% in 2022, and later skyrocketed by 152631.58% in 2024.
  • Medtronic's Asset Writedowns and Impairment (Quarter) stood at $515.0 million in 2021, then plummeted by 94.95% to $26.0 million in 2022, then crashed by 38.46% to $16.0 million in 2023, then surged by 68.75% to $27.0 million in 2024, then soared by 40.74% to $38.0 million in 2025.
  • Its Asset Writedowns and Impairment stands at $38.0 million for Q4 2025, versus $28.0 million for Q3 2025 and $27.0 million for Q2 2025.